Physician profile
Leslie E Lawrence
NPI 1598815888
$3,259.95
in general payments reported to CMS, 2019-2025
11 companies · $67.70 in 2025
The $67.70 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $372 · 2022: $1,205 · 2023: $715 · 2024: $900 · 2025: $67.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.79 |
| Education | $126.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $793.64 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $605.86 | 2022-2024 | Austedo, Austedo Xr, Uzedy |
| Abbvie INC. | $451.83 | 2021-2025 | |
| Indivior INC. | $310.12 | 2021-2024 | Perseris |
| Neurocrine Biosciences, INC. | $275.09 | 2021-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $275.07 | 2021-2025 | Invega, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $261.52 | 2021-2022 | |
| Lundbeck LLC | $142.40 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $66.58 | 2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $56.76 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $21.08 | 2024 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.